• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Basic Materials·301130.SZ
Share

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd Stocks

CN¥ 26.17Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 280.65M

CN¥ 26.17
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd specializes in the comprehensive process of pharmaceutical goods, encompassing their research, development, production, and distribution. Its portfolio features therapeutic drugs addressing conditions such as anemia, mental health issues, cardiovascular ailments, and various cancers. The firm also supplies traditional Chinese medicines and essential raw materials. These medicinal products are available in oral solid forms and as freeze-dried powder for injections. Established in 1993, the company operates from its headquarters in Panshi, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 11:30

Strive has been paying dividends every day for a month now. What risks does the company face?

16.07.2026 10:45

Samsung and SK Hynix shares plummeted ahead of TSMC's earnings report. The market is waiting for signals regarding AI

16.07.2026 10:30

Morning Roundup: New Strikes on Iran, Anthropic Heads Toward an IPO, and a Sell-Off in Asia

16.07.2026 09:30

"Market Leaders Face a Test of Resilience": Goldman Explains How to Protect Your Portfolio

16.07.2026 08:30

United Warned of $6 Billion in Additional Fuel Costs. Why the Profit Forecast Was Raised

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026